A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

NCT06320067 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3360

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

RADIATION: Stereotactic Ablative Body Radiotherapy (SABR)
OTHER: 177Lu-PSMA-617
DRUG: Androgen Deprivation Therapy (ADT)
DRUG: Androgen Receptor Signalling Inhibitor (ARPI)
RADIATION: Radiotherapy to Prostate ± Pelvic Nodes
DRUG: Docetaxel

Sponsor

University College, London

Collaborators

[object Object]
[object Object]